| Q30390167 | A Novel Endonuclease Inhibitor Exhibits Broad-Spectrum Anti-Influenza Virus Activity In Vitro |
| Q39322780 | A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control. |
| Q54626497 | A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries. |
| Q99711528 | Assessment of Immunogenicity of Adjuvanted Quadrivalent Inactivated Influenza Vaccine in Healthy People and Patients With Common Variable Immune Deficiency |
| Q34532079 | Available influenza vaccines: immunization strategies, history and new tools for fighting the disease |
| Q26801639 | B Cells and Functional Antibody Responses to Combat Influenza |
| Q64251725 | Back to the Future for Influenza Preimmunity-Looking Back at Influenza Virus History to Infer the Outcome of Future Infections |
| Q64245823 | Circulation of influenza A and B in the Czech Republic from 2000-2001 to 2015-2016 |
| Q64134590 | Comparative Immunogenicity of Enhanced Seasonal Influenza Vaccines in Older Adults: A Systematic Review and Meta-analysis |
| Q40072175 | Cost-effectiveness of inactivated seasonal influenza vaccination in a cohort of Thai children ≤60 months of age. |
| Q35886473 | Development of a heat-stable and orally delivered recombinant M2e-expressing B. subtilis spore-based influenza vaccine |
| Q28073431 | Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis |
| Q38595246 | Effectiveness of Influenza Vaccination for Individuals with Chronic Obstructive Pulmonary Disease (COPD) in Low- and Middle-Income Countries |
| Q36086281 | Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant |
| Q37638402 | Epidemiology of influenza B in Australia: 2001-2014 influenza seasons |
| Q30398507 | Evaluation of multivalent H2 influenza pandemic vaccines in mice |
| Q40131949 | Evolution and Vaccination of Influenza Virus |
| Q40092344 | Evolution of Influenza A Virus by Mutation and Re-Assortment |
| Q92510854 | Gulllain-Barre Syndrome After Trivalent Influenza Vaccination in Adults |
| Q92229180 | Hemagglutinin Quantitative ELISA-based Potency Assay for Trivalent Seasonal Influenza Vaccine Using Group-Specific Universal Monoclonal Antibodies |
| Q58699144 | Hormonal Regulation of Physiology, Innate Immunity and Antibody Response to H1N1 Influenza Virus Infection During Pregnancy |
| Q50420352 | Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults |
| Q90128048 | Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in pregnant women: a randomized, observer-blind trial |
| Q41995736 | Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea |
| Q26744404 | Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials |
| Q64137335 | Impact of European vaccination policies on seasonal influenza vaccination coverage rates: An update seven years later |
| Q64248501 | Imprinting and Editing of the Human CD4 T Cell Response to Influenza Virus |
| Q93266237 | Improving Vaccine-Induced Immunity: Can Baseline Predict Outcome? |
| Q92404505 | Influenza Vaccine With Consensus Internal Antigens as Immunogens Provides Cross-Group Protection Against Influenza A Viruses |
| Q64055452 | Influenza epidemiology and influenza vaccine effectiveness during the 2015-2016 season: results from the Global Influenza Hospital Surveillance Network |
| Q90525157 | Influenza in the school-aged population in Mexico: burden of disease and cost-effectiveness of vaccination in children |
| Q38221641 | Influenza vaccine effectiveness: best practice and current limitations of the screening method and their implications for the clinic. |
| Q49345779 | Influenza vaccines: Evaluation of the safety profile |
| Q35184572 | Influenza vaccines: challenges and solutions |
| Q37518273 | Influenza vaccines: unmet needs and recent developments |
| Q63627692 | Local-Level Adult Influenza and Pneumococcal Vaccination Disparities: Chicago, Illinois, 2015-2016 |
| Q27300233 | Matrix-M Adjuvated Seasonal Virosomal Influenza Vaccine Induces Partial Protection in Mice and Ferrets against Avian H5 and H7 Challenge |
| Q41072364 | Modeling Influenza Antigenic Shift and Drift with LEGO Bricks |
| Q26752546 | New Insights into the Generation of CD4 Memory May Shape Future Vaccine Strategies for Influenza |
| Q92498126 | Patterns of influenza B circulation in Latin America and the Caribbean, 2010-2017 |
| Q64999776 | Porcine parvovirus VP1/VP2 on a time series epitope mapping: exploring the effects of high hydrostatic pressure on the immune recognition of antigens. |
| Q91637698 | Preexisting subtype immunodominance shapes memory B cell recall response to influenza vaccination |
| Q30382787 | Protection against H5N1 Influenza Virus Induced by Matrix-M Adjuvanted Seasonal Virosomal Vaccine in Mice Requires Both Antibodies and T Cells. |
| Q37011571 | Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden |
| Q99553340 | Results of Influenza Vaccination: Short Follow-Up Study of a Turkish Population |
| Q35995259 | Retrospective public health impact of a quadrivalent influenza vaccine in the United States. |
| Q58603448 | Reverse transcription recombinase polymerase amplification with lateral flow dipsticks for detection of influenza A virus and subtyping of H1 and H3 |
| Q30390811 | Reversion of Cold-Adapted Live Attenuated Influenza Vaccine into a Pathogenic Virus |
| Q36714717 | Role of vaccination in the sustainability of healthcare systems |
| Q33904286 | Surveillance Study of Influenza Occurrence and Immunity in a Wisconsin Cohort During the 2009 Pandemic |
| Q30249793 | Surveillance systems and methods for monitoring the post-marketing safety of influenza vaccines at the Centers for Disease Control and Prevention. |
| Q40116011 | Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice |
| Q30205195 | Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses |
| Q36256314 | Technical guidelines for the application of seasonal influenza vaccine in China (2014-2015). |
| Q35750762 | Ten influenza seasons in France: distribution and timing of influenza A and B circulation, 2003-2013 |
| Q94407769 | The Economic Value of Vaccination: Why Prevention is Wealth |
| Q64104908 | The Future of Flu: A Review of the Human Challenge Model and Systems Biology for Advancement of Influenza Vaccinology |
| Q57166818 | The Future of Influenza Vaccines: A Historical and Clinical Perspective |
| Q38963385 | The PA Endonuclease Inhibitor RO-7 Protects Mice from Lethal Challenge with Influenza A or B Viruses |
| Q53280520 | The Respiratory Environment Diverts the Development of Antiviral Memory CD8 T Cells. |
| Q92666496 | Trends in governmental expenditure on vaccination programmes in the Netherlands, a historical analysis |
| Q93344976 | [The universal influenza vaccination in children with Vaxigrip Tetra® in Italy: an evaluation of Health Technology Assessment] |